Compare ADMA Biologics Inc (ADMA) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Apollo Global Management Ord Shs — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Apollo Global Management Ord Shs trades at $118.29 (market cap $68.80B). The key difference: Apollo Global Management Ord Shs is far larger — about 32.3× ADMA Biologics Inc's market cap, and Apollo Global Management Ord Shs pays a 1.89% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | APO | |
|---|---|---|
Market Cap | $2.13B | $68.80B |
Sector | Health | Financials |
52-Week High | $20.38 | $156.05 |
52-Week Low | $7.60 | $100.30 |
Enterprise Value | $2.20B | -$168.77B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Apollo Global Management (APO) trades at $119.33, up 0.61% with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.94, beating expectations, and maintains a 95.15% gross margin. Recent news highlights liquidity pressures in private credit funds, with Apollo capping withdrawals from its $25 billion Apollo Debt Solutions fund after 17% redemption requests in Q2 2026.
Outlook remains mixed: strong fee-generating AUM growth and dividend increases support bullish analyst targets averaging $149.71, but near-term risks include private credit liquidity concerns and multiple law firm investigations. The stock offers 25% upside to consensus target if liquidity pressures ease and earnings meet guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
